Target species
Milpro 4 mg/10 mg film-coated tablets for small cats and kittens
Cats (small cats and kittens).
Milpro 16 mg/40 mg film-coated tablets for cats
Cats >2kg
Indications for use
In cats: treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms) of the following species:
Cestodes:
Echinococcus multilocularis
Dipylidium caninum,
Taenia spp.,
Nematodes:
Ancylostoma tubaeforme,
Toxocara cati
The veterinary medicinal product can also be used in the prevention of heartworm disease (Dirofilaria immitis), if concomitant treatment against cestodes is indicated.
Contra-indications
Milpro for small cats and kittens: Do not use in kittens of less than 6 weeks of age and/or weighing less than 0.5 kg.
Milpro for cats: Do not use in cats weighing less than 2kg
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Special warnings
It is recommended to treat all the animals living in the same household concomitantly.
In order to develop an effective worm control programme local epidemiological information and the living conditions of the cat should be taken into account and therefore it is recommended to seek professional advice.
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
When D. caninum infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection.
Special precautions for use
Special precautions for safe use in the target species
No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.
Studies have shown that treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended. In the absence of data on cats with microfilaraemia, its use should be according to a benefit risk assessment by the attending veterinarian.
The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
As per good veterinary practice, animals should be weighed to ensure accurate dosing.
Ensure cats and kittens weighing between 0.5 kg and ≤2 kg receive the appropriate tablet strength (4 mg MBO/10 mg praziquantel) and the appropriate dose (1/2 or 1 tablet) for the corresponding weight band (1/2 tablet for cats weighing 0.5 to 1 kg ; 1 tablet for cats weighing >1 to 2 kg – 1 tablet).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Do not handle this veterinary medicinal product in case of hypersensitivity to the active substances or to any of the excipients.
Wash hands after use.
Part tablets should be returned to the open blister pack and stored in the carton.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.
Other precautions
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
Adverse events
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Hypersensitivity reaction1 Systemic disorders1 (e.g. Lethargy) Neurological disorders1 (e.g. Ataxia, Muscle tremor) Digestive tract disorders1 (e.g. Emesis, Diarrhoea) |
1 Especially in young cats.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation:
In a study, this combination of active substances was demonstrated to be well tolerated in breeding queens, including during pregnancy and lactation.
As a specific study with this product has not been performed, use during pregnancy and lactation only according to a benefit/risk assessment by the responsible veterinarian.
Interactions
The concurrent use of the combination praziquantel/milbemycin oxime with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the combination at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the product and other macrocyclic lactones. Also no such studies have been performed with reproducing animals
Administration routes and dosage
Oral use.
To ensure a correct dosage, body weight should be determined as accurately as possible.
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally as a single dose.
The veterinary medicinal product should be administered with or after some food.
The veterinary medicinal product is a small size tablet.
To aid with administration, the veterinary medicinal product has been coated with a meat flavour. The tablets can be divided into halves.
Depending on the bodyweight of the cat, the practical dosing is as follows:
| Weight | Tablets |
Milpro 4mg/10mg for small cats and kittens | 0.5 - 1 kg | ½ tablet |
| >1 - 2 kg |
1 tablet Milpro 16mg/40mg for cats | 2 - 4 kg | ½ tablet |
| >4 - 8 kg |
1 tablet | >8 - 12 kg |
The veterinary medicinal product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. The veterinary medicinal product has a duration of heartworm prevention of one month. For prevention of heartworm disease the use of a monosubstance is preferred.
Overdose
In a study conducted with the product administered at 1X, 3X and 5X the therapeutic dose, and for a duration which exceed the therapeutic indication, i.e. 3 times at 15 day-intervals, signs uncommonly reported at the recommended dose (see section 4.6) have been observed at 5-fold the therapeutic dose after the second and third treatments. These signs disappeared spontaneously within a day.